Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Otitis media guidelines for Australian Aboriginal and Torres Strait Islander children: summary of recommendations

The 2001 Recommendations for clinical care guidelines on the management of otitis media in Aboriginal and Torres Islander populations were revised in 2010. This 2020 update by the Centre of Research Excellence in Ear and Hearing Health of Aboriginal and Torres Strait Islander Children used for the first time the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.

Research

Topical versus systemic antibiotics for chronic suppurative otitis media

Chronic suppurative otitis media (CSOM), sometimes referred to as chronic otitis media (COM), is a chronic inflammation and often polymicrobial infection (involving more than one micro-organism) of the middle ear and mastoid cavity, characterised by ear discharge (otorrhoea) through a perforated tympanic membrane. The predominant symptoms of CSOM are ear discharge and hearing loss. Antibiotics are the most common treatment for CSOM, which act to kill or inhibit the growth of micro-organisms that may be responsible for the infection.

Research

Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis

Emerging evidence suggests young children are at greater risk of COVID-19 infection than initially predicted. However, a comprehensive understanding of epidemiology of COVID-19 infection in young children under five years, the most at-risk age-group for respiratory infections, remain unclear. We conducted a systematic review and meta-analysis of epidemiological and clinical characteristics of COVID-19 infection in children under five years.

Research

Screening and Management Practices for Polyoma (BK) Viremia and Nephropathy in Kidney Transplant Recipients From the Lands Down Under: Addressing the Unknowns and Rationale for a Multicenter Clinical Trial

BK polyomavirus infection in transplanted kidneys that leads to BK virus–associated nephropathy (BKVAN) is an important cause of allograft loss and has limited treatment options. Recent data suggest that BK viremia affects approximately 10% of people within the first 12 months following kidney transplantation. Among recipients with BKVAN, the overall risk of allograft loss is substantially increased, estimated to be 50% within 5 years of diagnosis.

News & Events

WA’s nation-leading immunisation program for babies slashes RSV hospital admissions

An Australian-first study demonstrating the effectiveness of a new immunisation against respiratory syncytial virus (RSV) for babies found it to be almost 90 per cent effective in reducing hospitalisation rates and helped more than 500 WA families avoid a hospital stay.

News & Events

Major grants fuel child health research

Six researchers from The Kids Research Institute Australia have been awarded $8.9 million in prestigious Investigator Grants from the National Health and Medical Research Council.

News & Events

Five researchers from The Kids awarded Early Career Child Health Researcher Fellowships

Five researchers from The Kids Research Institute Australia have been awarded three-year fellowships with the aim of keeping more WA-based PhD graduates involved in child health research.

News & Events

World-first nasal spray whooping cough vaccine aims to protect young bubs

Tiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.

News & Events

International collaboration awarded $US8 million to design world-first diagnostic tool for acute rheumatic fever

Researchers from The Kids Research Institute Australia are joining forces with international experts in acute rheumatic fever (ARF) and rheumatic heart disease (RHD) to transform the diagnosis of these diseases thanks to an $US8 million grant from the Leducq Foundation.

About the Vaccine Trials Group

The Vaccine Trials Group was formed in March 1999 to provide a coordinated approach to the development, delivery, assessment and promotion of vaccines.